Renal Anemia Treatment Market

Renal Anemia Treatment Market Outlook (2024 to 2034)

The global renal anemia treatment market size is estimated at a valuation of US$ 6.85 billion in 2024 and thereafter expand at a CAGR of 7.5% to reach US$ 14.15 billion by the end of 2034. Renal anemia is a type of chronic disease, also referred to as anemia of chronic kidney disease (CKD), and is a form of normocytic, normochromic, hyperproliferative anemia.

Renal anemia is frequently associated with poor outcomes in chronic kidney disease and confers an increased mortality risk. These risks are making people actively look for treatment and helping them prolong their life. Treatment is directed toward improving renal function and increasing blood cell production. In recent years, the prevalence of kidney diseases has been increasing steadily. These factors are contributing to renal anemia treatment market growth.

Key Market Growth Drivers

• There has been a considerable increase in the consumption of junk food, leading to health issues such as iron deficiency, vitamin B12 deficiency, and folate deficiency, causing diseases such as renal anemia. This is prompting individuals towards treatment.
• Treatment of anemia of chronic renal disease primarily focuses on improving the production of red blood cells; among the most popular medications is epoetin.
• Renal anemia predominantly affects the age group between 60 and 65, making them primary targets for renal anemia medicine manufacturers; the demand for such treatments is growing due to the increasing susceptibility of kidney-related disorders among the aging population worldwide.
• More people are making efforts to maintain their health from a young age, prompting the younger population to seek treatments for quicker healing and optimal kidney function, thus contributing to the expansion of the renal anemia treatment market size.
• Renal anemia is mainly caused by a deficiency of iron-rich foods containing beta-carotene, such as apricots and beetroot. Doctors recommend natural treatments alongside artificial medicines.
• Ongoing research and developments continually enhance market conditions, introducing advanced techniques to address this chronic disease.
• With a huge aging population, East Asia holds a significant renal anemia treatment market share. The market in East Asia is projected to expand at a CAGR of 7.5% from 2024 to 2034.
• Manufacturers are heavily investing in refining their strategies through research into new approaches like cost-effectiveness and partnerships to secure a substantial share of the market.

Report Attributes	Details
Renal Anemia Treatment Market Size (2024E)	US$ 6.85 Billion
Forecasted Market Value (2034F)	US$ 14.15 Billion
Global Market Growth Rate (2024 to 2034)	7.5% CAGR
Canada Market Growth Rate (2024 to 2034)	7.4% CAGR
China Market Value (2034F)	US$ 952 Million
North America Market Share (2024E)	45.5%
East Asia Market Share (2034F)	17.2%
Key Companies Profiled	Pfizer Inc. Janssen Pharmaceuticals, Inc. Teva Pharmaceutical Industries Sanofi AbbVie Inc. Covis Pharma Eli Lilly and Company FibroGen GlaxoSmithKline

Which Renal Anemia Treatment Market Trends are Healthcare Providers Leveraging?

“Increasing Incidence of Iron Deficiency among Pregnant Women”

High risk of renal anemia due to iron deficiency among pregnant women is projected to drive sales of new medications for treating renal anemia. This often occurs as blood volume increases during pregnancy, prompting the body to utilize iron to produce more blood for fetal oxygen supply.

Urgent need for alternative treatments for renal anemia, which can lead to preterm deliveries and postpartum depression, is projected to boost sales. This condition may also increase mortality rates among newborns shortly before or after birth, as well as result in lower birth weights.

“Advancements in Renal Anemia Diagnosis Technology”

One of the primary factors driving the growth of the market is the rising incidence of renal disorders within the population, leading to kidney dysfunction.

The aging population, particularly susceptible to renal anemia due to age-related kidney issues, along with an uptick in chronic conditions like hypertension, type 2 diabetes, and cardiovascular diseases, further heightens the risk of renal anemia, thus fueling demand for associated treatment. Advancements in renal anemia diagnosis technology, coupled with increased research and drug development for renal anemia treatment, also play pivotal roles in driving the renal anemia treatment market growth.

What’s Acting as a Hindrance to Market Expansion?

“Side Effects Associated with Renal Anemia Medications”

In many instances, medications used in renal anemia treatment may cause side effects. These incidents lead to a negative reputation for manufacturers. The responses to medications differ from one individual to another, and doctors must ensure that they consider each patient's unique physiology when prescribing doses and formulations.

Market players must meticulously scrutinize the constituents of their medications and enhance quality checks to ensure error-free production. Major industry players are making investments in production facilities to maintain their market presence and contribute to market expansion.

Country-wise Evaluation

The markets in developed countries, such as the United States, Canada, and Japan, are expanding at a significant pace backed by rapid technological advancements that are bringing innovation in the medical field. This ensures timely availability of medical equipment and medication to speed up the healing process for patients. The South Korean market is forecasted to expand at a CAGR of 7.7% from 2024 to 2034.

How is the United States Government Contributing to Rising Sales of Renal Anemia Treatment Solutions?

“Favorable Reimbursement Policies Boosting Sales of Medications for Renal Anemia”

Attribute	United States
Market Value (2024E)	US$ 2.76 Billion
Growth Rate (2024 to 2034)	7.9% CAGR
Projected Value (2034F)	US$ 5.88 Billion

Advancements in technology have led to enhanced treatment options in the United States. This is projected to drive the growth of the market in the country during the forecast period. Moreover, the consistent implementation of favorable reimbursement policies by the government is projected to bolster sales of renal anemia medications.

• According to the American Family Physician, the prevalence of iron deficiency anemia stands at 20% in black and Mexican-American women, 9% to 12% in non-Hispanic White women, and 2% in adult males. Around 9% of individuals aged over 65 with this condition develop gastrointestinal cancer. These numbers are projected to increase in the near future, consequently boosting sales of medications for renal anemia.

Why are Renal Anemia Treatment Providers Investing in China?

“Government Initiatives Aimed at Providing Low-Cost Acute Anemia Treatment”

Attribute	China
Market Value (2024E)	US$ 463 Million
Growth Rate (2024 to 2034)	7.5% CAGR
Projected Value (2034F)	US$ 952 Million

Several initiatives by the government in China to supply low-cost acute anemia treatment medications are advantageous to treatment providers in East Asia. Growing public awareness of both the treatment and the diagnosis of this condition is also driving market expansion.

• In November 2020, for example, researchers from many Chinese educational institutions performed a study to assess the incidence of renal anemia and anemia in pregnant women. Nearly 13.9% of Chinese women were diagnosed with iron deficiency anemia, and around 19.8% were diagnosed with anemia. The growing number of comparable research investigations in this nation is expected to drive market growth.

Category-wise Insights

Based on distribution channel, the hospital segment is forecasted to expand at a CAGR of 7.7% from 2024 to 2034. This has prompted manufacturers to establish connections with a range of hospitals to enhance their market presence.

What is Prompting Market Players to Expand Erythrocyte Supplement Production?

“Erythrocyte Supplements Proving Effective in Treating Iron Deficiency-related Renal Disorders”

Attribute	Erythrocyte
Segment Value (2024E)	US$ 5.68 Billion
Growth Rate (2024 to 2034)	7.4% CAGR
Projected Value (2034F)	US$ 11.65 Billion

Renal anemia is predominantly caused by iron deficiency, and treatments involving erythrocytes help increase the body's red blood cell count. Market players recognize this demand and are investing in expanding their production capacity of erythrocyte supplements to contribute to market growth.

Which Route of Administration is Preferred by Patients and Healthcare Providers?

“Patient Demand for Quick Healing Driving Preference for Parenteral Route of Administration”

Attribute	Parenteral
Segment Value (2024E)	US$ 4.47 Billion
Growth Rate (2024 to 2034)	7.4% CAGR
Projected Value (2034F)	US$ 9.15 Billion

The parenteral route of administration involves injection or infusion. These methods are preferred more as they are quick to execute as compared to the oral route. Patients seek quick and effective healing, which makes the parenteral route of administration more popular in the market among patients and healthcare providers.

Business Competition

Key players in the renal anemia treatment market are focused on various marketing methods to broaden their geographical reach and product portfolios.

Some well-known firms are looking to collaborate with foreign and local merchants to market their in-house acute anemia therapy drugs. Meanwhile, a few well-known businesses are working to create novel treatments and obtain regulatory permission for the sale of their products, thus contributing to the expansion of the market.

• In February 2022, the European Commission granted authorization to Global Blood Therapeutics, Inc. for Oxbryta (voxelotor) to treat hemolytic anemia in sickle cell disease patients aged 12 and above. This is the first approval in Europe for targeting red blood cell damage and directly addressing the molecular cause of sickling.

Key Segments of Renal Anemia Treatment Market Research

• By Product Type :

  • Iron Supplements
  • Erythrocyte Supplements

• By Route of Administration :

  • Oral
  • Parenteral

• By Distribution Channel :

  • Hospitals
  • Retail Pharmacies
  • Mail Order

• By Region :

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia & Oceania
  • Middle East & Africa